vendredi 15 février 2019

Onco Actu du 15 février 2019


1.4 BIOLOGIE - TECHNOS



Stitching together a ‘Google Earth’ for cancer [Cancer Research UK]











2. ETIOLOGIE



Roswell Park Researchers Identify Protein That Contributes to Racial Disparities in Prostate Cancer [Roswell Park]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Consensus Guideline on Genetic Testing for Hereditary Breast Cancer [American Society of Breast Surgeons]










All breast cancer patients should get genetic testing, surgeons say [CNN]











Breast surgeons say all breast cancer patients should be offered genetic testing [Washington Post]











5. TRAITEMENTS



Use of Gastric Acid Suppressants May Negatively Impact Survival Outcomes in Sarcoma Patients Treated with Pazopanib [AACR]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Antibody could increase cure rate for blood, immune disorders [Stanford Medicine]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



TCR²’s IPO Raises $75M to Bring Cancer Cell Therapy to Solid Tumors [Xconomy]











A CAR T-Cell Therapy for Multiple Childhood Cancers? [NCI]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



Merck aims for prostate cancer dominance with 3 new phase 3 Keytruda studies [Fierce Pharma]











Merck plans trio of Phase 3 Keytruda studies in prostate cancer [Biopharma Dive]










Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials [Merck]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Vor Biopharma Completes $42 Million Series A Financing Round to Advance Lead Cell Therapy Product Candidate for the Treatment of Acute Myeloid Leukemia [Vor]











5.2 PHARMA



Eagle and Mystic lead AstraZeneca’s cancer clear out [Fierce Pharma]











AstraZeneca retires Medimmune name amid sales turnaround [Biopharma Dive]











“MedImmune” brand to be retired as biologics integrate into AstraZeneca’s new R&D structure [MedImmune]











AstraZeneca drops an OX40 cancer drug candidate in Q4 pipeline cleanup [EndPoints]











5.4 TRAITEMENTS - ECONOMIE



NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company [NICE]










5.5.3 ASCO (PROSTATE)



Bayer’s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer [Bayer]











Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer [BMS]











Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD) [Janssen]











Immunotherapy combination generates responses against castration-resistant metastatic prostate cancer [MD Anderson Cancer Center]











Bayer stresses drug's tolerability in bid for prostate cancer market [Reuters]











6.1 OBSERVATION



Black-White Cancer Mortality Gap Nearly Eliminated in Some Age Groups [ACS]










Racial Disparities In Cancer Incidence And Survival Rates Are Narrowing [NPR]











Black-white cancer disparities narrow sharply amid progress against common malignancies [Washington Post]











6.2 IMPLANTS MAMMAIRES



FDA issues warning letter to doctor for illegally marketing unapproved device with claims to prevent and treat tightening of scar tissue around breast implants [FDA]











6.7.2 APPLIS



Helping Patients Navigate Cancer With The Power And Simplicity of Waze [Forbes]